Storia in 7 fonti

Roche commits to lean-mass preservation with Hanmi obesity deal

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 g fa

Roche commits to lean-mass preservation with Hanmi obesity deal

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.

originale

Timeline cronologica

lunedì 24 agosto 2026·biopharmadive.com
Roche commits to lean-mass preservation with Hanmi obesity deal
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
lunedì 24 agosto 2026·morningstar.com
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

Roche commits to lean-mass preservation with Hanmi obesity deal

Confronto fonti

Roche commits to lean-mass preservation with Hanmi obesity deal

Timeline cronologica

Roche commits to lean-mass preservation with Hanmi obesity deal

Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset

Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate - The Korea Times

Roche snags rights to South Korean obesity treatment

Hanmi signs record $2.3b obesity drug deal with Genentech

Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

Hanmi signs record $2.3b obesity drug deal with Genentech

Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate - The Korea Times

Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset

Roche snags rights to South Korean obesity treatment

Hanmi dispara 30% após acordo de US$ 2,31 bi com subsidiária da Roche para tratamento de obesidade